Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Hepatology. 2015 Apr;61(4):1295-305. doi: 10.1002/hep.27639. Epub 2015 Feb 24.
Autoimmune polyendocrine syndrome type 1 (APS-1) is caused by mutations of the autoimmune regulator (AIRE) gene. Mouse studies have shown that this results in defective negative selection of T cells and defective early seeding of peripheral organs with regulatory T cells (Tregs). Aire deficiency in humans and mice manifests as spontaneous autoimmunity against multiple organs, and 20% of patients develop an autoimmune hepatitis (AIH). To study AIH in APS-1, we generated a murine model of human AIH on a BALB/c mouse background, in which Aire is truncated at exon 2. A subgroup of 24% of mice is affected by AIH, characterized by lymphoplasmacytic and periportal hepatic infiltrates, autoantibodies, elevated aminotransferases, and a chronic and progressive course of disease. Disease manifestation was dependent on specific Aire mutations and the genetic background of the mice. Though intrahepatic Treg numbers were increased and hyperproliferative, the intrahepatic CD4/CD8 ratio was decreased. The targets of the adaptive autoimmune response were polyspecific and not focussed on essential autoantigens, as described for other APS-1-related autoimmune diseases. The AIH could be treated with prednisolone or adoptive transfer of polyspecific Tregs.
Development of AIH in APS-1 is dependent on specific Aire mutations and genetic background genes. Autoimmune response is polyspecific and can be controlled by steroids or transfer with Tregs. This might enable new treatment options for patients with AIH.
自身免疫性多内分泌腺综合征 1 型(APS-1)是由自身免疫调节因子(AIRE)基因突变引起的。小鼠研究表明,这导致 T 细胞的阴性选择缺陷和调节性 T 细胞(Treg)在周围器官的早期定植缺陷。人类和小鼠的 AIRE 缺陷表现为对多种器官的自发性自身免疫,20%的患者发生自身免疫性肝炎(AIH)。为了研究 APS-1 中的 AIH,我们在 BALB/c 小鼠背景下生成了一种人类 AIH 的小鼠模型,其中 AIRE 在第 2 外显子处截断。有 24%的小鼠受到 AIH 的影响,其特征为淋巴浆细胞和门脉周围肝浸润、自身抗体、转氨酶升高以及疾病的慢性和进行性病程。疾病表现取决于特定的 AIRE 突变和小鼠的遗传背景。尽管肝内 Treg 数量增加且过度增殖,但肝内 CD4/CD8 比值降低。适应性自身免疫反应的靶标是多特异性的,而不是针对其他 APS-1 相关自身免疫疾病中描述的必需自身抗原。AIH 可以用泼尼松龙或多特异性 Treg 的过继转移来治疗。
APS-1 中 AIH 的发展取决于特定的 AIRE 突变和遗传背景基因。自身免疫反应是多特异性的,可以通过类固醇或 Treg 转移来控制。这可能为 AIH 患者提供新的治疗选择。